Procter & Gamble Company (NYSE:PG) saw an uptick in early trading on Tuesday after unveiling a FQ2 earnings report that left investors with mixed sentiments. The company’s organic sales rose 4% during the quarter— a slightly shy of the +4.6% consensus. However, pricing exhibited a 4% increase, while volume saw a 1% decline. Notably, the EPS surged 16% year-over-year to $1.84, comfortably surpassing the $1.70 consensus.
Within the organic sales growth, the Health Care segment witnessed a 2% uptick, buoyed by a 5% increase in prices. While Oral Care saw a mid-single-digit rise due to escalated pricing and premium product mix, it experienced volume declines, especially in Latin America and Asia. Contrastingly, Personal Health Care’s organic sales dwindled by a low single digit, primarily influenced by volume declines and an unfavorable mix due to a market decline of respiratory products, albeit offset by increased pricing.
Meanwhile, the Fabric and Home Care segment experienced a substantial 6% organic sales surge, driven by mid-single-digit spikes in both Fabric Care and high-single-digit growth in Home Care due to a combination of increased pricing, favorable product mix, and volume growth from innovation. P&G’s Grooming segment also stood strong with a noteworthy 9% organic sales surge, propelled by elevated pricing, premium product mix, and volume growth.
P&G’s gross margin rate particularly stood out, showing a remarkable 520 basis points improvement for the quarter, or 590 basis points on a currency-neutral basis. This leap was attributed to several factors, including 240 basis points from gross productivity savings, a 200-basis-point benefit from favorable commodity costs, and a 190-basis-point rise from increased pricing—despite 40 basis points of product reinvestments and other impacts. The 52.7% gross margin rate notably soared past the consensus estimate of 50.3%.
The company’s core operating margin for the quarter also illustrated impressive growth, climbing 400 basis points from a year ago, or a remarkable 470 basis points on a currency-neutral basis. This included substantial contributions from 340 basis points of gross productivity savings.
In a statement, P&G’s CEO affirmed the company’s commitment to its integrated strategy and highlighted the team’s execution of the same as the driving force behind their strong momentum. This united approach encapsulates a focused product portfolio in daily use categories, emphasizing performance that propels brand choice, overall superiority, productivity, constructive disruption, and an agile and accountable organization.
Looking ahead, Procter & Gamble (PG) has issued its guidance for fiscal year 2024, anticipating all-in sales growth in the range of 2% to 4% to $83.7B to $85.3B, falling marginally short of the $84.9B consensus, with organic revenue growth projected at +4% to +5%. The company aims for an EPS of $6.37 to $6.43, slightly below the $6.41 consensus.
Notably, shares of Procter & Gamble (PG) surged by 1.01% in premarket action on Tuesday, reaching $149.36. The upcoming conference call, where P&G management is set to offer additional updates, could pique the interest of key players such as Church & Dwight (CHD), Kimberly-Clark (KMB), Colgate-Palmolive (CL), and Clorox (CLX).